Ali Kalem

8PUBLICATIONS
149CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 29, 2026
Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|May 27, 2026
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Sep 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG).

Ali Kalem, Tulay Kus, Taha Koray Sahin

Pageof 2

Frequent Collaborators

5 joint publications

Mustafa Seyyar

5 joint publications

Elif Sahin

4 joint publications

Taha Koray Sahın

4 joint publications

Berkan Karabuga